Expand all sections

Ozekibart

Extended indication Ozekibart monotherapie voor de behandeling van gemetastaseerd of niet-reseceerbaar conventioneel cho
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Ozekibart
Domain Oncology
Reason of inclusion New medicine (specialité)
Main indication Oncology other
Extended indication Ozekibart monotherapie voor de behandeling van gemetastaseerd of niet-reseceerbaar conventioneel chondrosarcoom bij volwassenen en ouderen
Manufacturer Inhibrx Biosciences
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)
Additional remarks Tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5).

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date June 2025
Expected Registration July 2026
Orphan drug No
Registration phase Clinical trials
Additional remarks Indieningsdatum en verwachte registratie op basis van IHSI-inschatting.

Therapeutic value

Current treatment options Operatie.
Therapeutic value No estimate possible yet
Substantiation Op dit moment loopt er nog een fase 2 studie.
References NCT04950075 (ChonDRAgon)

Expected patient volume per year

Patient volume

40

Market share is generally not included unless otherwise stated.
References Kanker.nl (1)
Additional remarks Elk jaar krijgen ongeveer 40 mensen de diagnose chondrosarcoom (1).

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.